Edition:
United States

La Jolla Pharmaceutical Co (LJPC.OQ)

LJPC.OQ on NASDAQ Stock Exchange Capital Market

16.99USD
18 Oct 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$16.99
Open
$17.75
Day's High
$17.77
Day's Low
$16.80
Volume
70,359
Avg. Vol
131,268
52-wk High
$41.24
52-wk Low
$15.99

Latest Key Developments (Source: Significant Developments)

La Jolla Pharmaceutical Company Reports Qtrly Loss Per Share Of $2.02
Wednesday, 8 Aug 2018 04:01pm EDT 

Aug 8 (Reuters) - La Jolla Pharmaceutical Co ::MPANY ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2018 AND RECENT CORPORATE PROGRESS.QUARTERLY LOSS PER SHARE $2.02.QUARTERLY TOTAL REVENUE $1.6 MILLION VERSUS NIL REVENUE.  Full Article

Broadfin Capital Reports 5 Percent Passive Stake In La Jolla Pharmaceutical - SEC Filing‍​
Thursday, 11 Jan 2018 05:12pm EST 

Jan 11 (Reuters) - La Jolla Pharmaceutical Co ::BROADFIN CAPITAL LLC REPORTS 5 PERCENT PASSIVE STAKE IN LA JOLLA PHARMACEUTICAL CO AS OF JAN 9 - SEC FILING‍​.  Full Article

La Jolla Pharmaceutical Says Cash Resources Are Expected To Fund Co Into Second Half Of 2018
Friday, 29 Dec 2017 04:40pm EST 

Dec 29 (Reuters) - La Jolla Pharmaceutical Co ::LA JOLLA PHARMACEUTICAL SAYS CASH RESOURCES ARE EXPECTED TO FUND CO INTO SECOND HALF OF 2018 - SEC FILING.  Full Article

La Jolla Says FDA Approved Drug To Treat Critically Low Blood Pressure
Thursday, 21 Dec 2017 06:17pm EST 

Dec 21 (Reuters) - La Jolla Pharmaceutical Co ::U.S. FOOD AND DRUG ADMINISTRATION SAYS APPROVED GIAPREZA (ANGIOTENSIN II) TO TREAT DANGEROUSLY LOW BLOOD PRESSURE.U.S. FDA SAYS GRANTED THE APPROVAL OF GIAPREZA TO LA JOLLA PHARMACEUTICAL COMPANY.U.S. FDA - APPROVES GIAPREZA (ANGIOTENSIN II) INJECTION FOR INTRAVENOUS INFUSION TO INCREASE BLOOD PRESSURE IN ADULTS WITH SEPTIC/OTHER DISTRIBUTIVE SHOCK.  Full Article

La Jolla Pharmaceutical Initiates Multicenter, Randomized, Phase 2 Clinical Study Of LJPC‑401
Monday, 18 Dec 2017 09:00am EST 

Dec 18 (Reuters) - La Jolla Pharmaceutical Co ::INITIATION OF MULTICENTER, RANDOMIZED, PHASE 2 CLINICAL STUDY OF LJPC‑401 IN PATIENTS WITH HEREDITARY HEMOCHROMATOSIS.  Full Article

La Jolla Pharma files for mixed shelf of up to $150 mln ‍​
Friday, 27 Oct 2017 05:42pm EDT 

Oct 27 (Reuters) - La Jolla Pharmaceutical Co :Files for mixed shelf of up to $150 million - SEC filing‍​.  Full Article

La Jolla reports Q3 loss $1.19/shr
Thursday, 26 Oct 2017 05:10pm EDT 

Oct 26 (Reuters) - La Jolla Pharmaceutical Co :La Jolla Pharmaceutical Company announces financial results for the three and nine months ended September 30, 2017 and recent corporate progress.Q3 loss per share $1.19.Q3 earnings per share view $-1.24 -- Thomson Reuters I/B/E/S.La Jolla Pharmaceutical-‍as of Sept 30, 2017, co had $120.8 million in cash,cash equivalents, versus $65.7 million of cash and cash equivalents at Dec 31, 2016​.  Full Article

Prudential Financial reports 10.1 pct passive stake ​in La Jolla Pharmaceutical
Tuesday, 10 Oct 2017 12:35pm EDT 

Oct 10 (Reuters) - La Jolla Pharmaceutical Co ::Prudential Financial Inc reports 10.1 percent passive stake ​in La Jolla Pharmaceutical Co as of Sept 30 - sec filing ‍.  Full Article

BRIEF-La Jolla Pharmaceutical Co Announces $125 Mln Royalty Financing Agreement With Healthcare Royalty Partners

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES $125 MILLION ROYALTY FINANCING AGREEMENT WITH HEALTHCARE ROYALTY PARTNERS Source text for Eikon: Further company coverage: